MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 11..20 of 82 - per page Previous page Next page
Order by
Novel small molecule inhibitors of c-Met signaling; these small molecules selectively bind to c-Met and have an IC50 in the micromolar range. More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
A cancer therapy and diagnostic that utilizes a variation of "Boron Neutron Capture Therapy" to deliver intense, short-lived, therapeutic doses of radiation specifically to active tumor sites. More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
A powerful technology for the simultaneous monitoring of protein kinase activities in cell and tissue extracts using a multiplexed electrochemical assay More
Synthesis of several tetrahalogenated thalidomide derivatives that are potentially more anti-angiogenic than thalidomide More
Peptides and antigen epitopes specific for RCC for use in the diagnosis, vaccination, or adoptive infusion of antigen specific T cells to treat patients with metastatic RCC More
Methods and compositions for the improved treatment of metastatic tumors by using a CXCR4 antagonist in conjunction with conventional monoclonal antibody based immunotherapy or immunostimulatory chemotherapeutics. More
Displaying 11..20 of 82 - per page Previous page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioPartnering America
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us